Financial Performance
5Y price score: (46)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 19.5%
US$ Per
Share
By default your notes are visible only to you.
73.3
52-week range
106.3
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
5.1 %
Dividend Yield TTM
3.4 %
Market cap $
$ 106,500
Price / Earnings TTM
22.3
Price / Book TTM
2.2
PEG TTM
6.7
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(3.9) %
(23.4) %
19.5 %
Free cash flow per share growth
4.8 %
16.8 %
44 %
Earnings per share growth
3.3 %
40.2 %
50.4 %
Founded: 1,949
Employees: 95,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q4 (Jun 3, 2026)
1) Strong Financial Performance
- Q4 revenue reached $9.8 billion, up 9.9% reported and 6.6% organically.
- Full fiscal year revenue was $36.4 billion, marking an 8.4% increase reported and 5.8% organically, the strongest performance in a decade.
- Adjusted EPS for Q4 was $1.55, exceeding expectations, while FY '26 adjusted EPS was $5.53.
- Free cash flow for FY '26 was $5.4 billion, the highest since 2022.
2) Segment Highlights and Growth Drivers
- Cardiac Ablation Solutions (CAS) saw 78% growth globally, with 145% growth in PFA.
- Symplicity Spyral for hypertension annualized at $100 million, with significant clinical data supporting its efficacy.
- Hugo surgical robotics is gaining traction, with procedure volumes growing 2x to 3x the market rate.
- Altaviva for urinary incontinence is gaining momentum, with active implanters up 3x sequentially.
- Diabetes business delivered 15% growth reported and 8.1% organic, with the upcoming launch of MiniMed Flex anticipated to drive further growth.
3) Strategic Focus and Investments
- Continued focus on M&A and partnerships, with nearly $2 billion in investments announced or closed.
- Recent acquisitions include CathWorks, Scientia, and SPR Therapeutics, aimed at enhancing product offerings in high-growth segments.
- The company is strategically investing in innovation and expanding its product pipeline, particularly in electrophysiology and surgical robotics.
4) Challenges and Market Dynamics
- The TAVR business faced challenges in the U.S. due to low-risk data, but has stabilized recently.
- Tariffs impacted the business by $74 million in Q4, with an anticipated $250 million total impact for FY '27.
- The company is navigating a dynamic macro environment but remains focused on operational efficiency and cost management.
5) Guidance and Outlook
- For FY '27, Medtronic expects organic revenue growth of 6.75% to 7.25%, with a strong start anticipated in Q1.
- EPS guidance for FY '27 is set at $5.90 to $6.00, incorporating various headwinds and growth drivers.
- The company plans to maintain its focus on innovation and capital allocation to support growth in key segments.
Bottom line: Medtronic's robust Q4 and FY '26 performance, driven by strong growth in key segments and strategic investments, positions the company well for continued growth in FY '27 despite facing some market challenges. The focus on innovation and operational efficiency should provide a solid foundation for shareholder value creation.
Annual Reports, Presentations And IR Contacts
Go to the websiteMedtronic plc — Financial Overview, Stock Price, Market Cap
Medtronic plc is a company. Founded in 1949. As of July 20, 2026, the company's market capitalization is $106500160000 with a current stock price of $83.20.